<DOC>
	<DOCNO>NCT02170038</DOCNO>
	<brief_summary>The clinical phase I study aim investigate conversion contraceptive compound norethisterone within body towards contraceptive compound ethinylestradiol . Therefore concentration ethinylestradiol measure blood sample administration single intramuscular dose norethisterone . In comparison arm concentration ethinylestradiol measure blood sample administration pill contain ethinylestradiol .</brief_summary>
	<brief_title>Clinical Study Investigating Conversion Contraceptive Compound Norethisterone Within Body Towards Contraceptive Compound Ethinylestradiol</brief_title>
	<detailed_description />
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Norethindrone enanthate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Healthy female subject Age : 18 45 year ( inclusive ) first screen examination / visit Body mass index ( BMI ) : equal 18 equal 30 kg / mÂ² At least 3 month since delivery , abortion , lactation first screen examination / visit Incompletely cure preexisting disease assume absorption , distribution , metabolism , elimination effect study drug normal Liver disease , kidney disease , metabolic disorder , thyroid disorder know suspected malignant benign tumor Presence history venous arterial thrombotic/thromboembolic event Migraine neurologic symptom ( complicated migraine ) Clinically significant depression Pancreatitis history thereof associate severe hypertriglyceridemia Use systemic topical medicine substance oppose study objective might influence</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Drug Kinetics</keyword>
</DOC>